Ex parte MATTSSON et al. - Page 7




                      Appeal No. 1996-1009                                                                                                                                                    
                      Application No. 07/949,551                                                                                                                                              


                                 collaterals in dogs, there has been no showing that the sulfated heparins of the                                                                             
                                 references do not possess these properties. [Answer, page 5, first full paragraph.]                                                                          

                                 According to appellants, “[t]he prior art does not suggest treating patients for angina pectoris                                                             

                      as recited in the claims now on appeal.  In addition, the heparin derivatives employed pursuant to the                                                                  

                      present invention are quite different from the products suggested by the prior art” (brief, page 4, lines 1-                                                            

                      3).                                                                                                                                                                     

                                 As to treatment of angina pectoris, the examiner’s position is two-fold.  First, “appellant’s                                                                

                      specification acknowledges that it is known in the art to use derivatives of heparin for treatment of                                                                   

                      angina (see page 1 of the Background)” (answer, page 7).  Secondly, since “[a]ngina is a symptom                                                                        

                      directly related to an atherosclerosis situation.  If the references teach prevention or treatment of the                                                               

                      underlying cause of angina, it therefore follows that prevention or treatment of angina itself is inherently                                                            

                      taught” (answer, page 7).  First, the specification states that heparin, not derivatives of heparin, has                                                                

                      been found to improve collateral circulation in patients with effort angina (page 1, lines 14-19).                                                                      

                      Secondly, the claimed invention requires treating a patient that has already has angina pectoris.                                            3                          

                      Atherosclerosis is not angina pectoris, just as angina pectoris is not myocardial infarction.  That is not to                                                           


                                 3   While the record in this appeal indicates that the examiner performed a database search of the PTO’s                                                     
                      automated patent search system (USPAT) and of chemical abstracts (CAS) for oxidized, reduced and/or sulfated                                                            
                      heparin derivatives, it does not appear that a database search linking heparin to angina pectoris was ever performed.                                                   
                      Therefore, in the event of further prosecution, the examiner should consider conducting a database search, e.g., in                                                     
                      MEDLINE, CAS, BIOSIS (biological abstracts) and the PTO’s own automated patent search system, linking at least                                                          
                      “heparin” to “angina pectoris,” e.g., within 10 words, and to publication years of 1992 or earlier, given the filing date                                               
                      of this application.                                                                                                                                                    
                                                                                           - 7 -                                                                                              





Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  Next 

Last modified: November 3, 2007